Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform

Background: Anticancer vaccines could represent a valuable complementary strategy to established therapies, especially in settings of early stage and minimal residual disease. HER-2 is an important target for immunotherapy and addressed by the monoclonal antibody trastuzumab. We have previously gene...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Autores principales: Singer, Josef, Manzano-Szalai, Krisztina, Fazekas, Judit, Thell, Kathrin, Bentley-Lukschal, Anna, Stremnitzer, Caroline, Roth-Walter, Franziska, Weghofer, Margit, Ritter, Mirko, Pino Tossi, Kerstin, Hörer, Markus, Michaelis, Uwe, Jensen-Jarolim, Erika
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2016
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006910/
https://ncbi.nlm.nih.gov/pubmed/27622022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1171446
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares